China Doesn't Just Compete in Advanced Technology — It Dominates. Here's the Catch.

There's a version of the China story that's become almost too obvious to state: China dominates advanced manufacturing at a scale that has no real historical precedent among industrial economies. I want to make the strongest possible version of that case, with real numbers, and then complicate it — because the honest picture is more interesting, and more useful, than either the triumphalist or the dismissive version of this argument.

The case for dominance, stated plainly

Start with EV batteries. Seven of the world's top ten battery manufacturers are Chinese, and together they account for 72.6% of global EV battery usage as of early 2026. CATL alone holds 40.2% of the global market; add BYD's 14.4% and two Chinese companies control well over half of the entire world's EV battery supply. China accounts for more than 80% of total global battery cell production.

Solar is, if anything, more extreme. China controls roughly 93% of global polysilicon production, 97% of wafers, and 92% of cells — dominance so complete across every stage of the supply chain that "market share" almost undersells it. This isn't a country that leads in solar manufacturing; it's a country that the rest of the world's solar industry currently cannot function without.

Rare earths follow the same pattern at the extraction and processing stage: roughly 70% of global mining and close to 90% of global processing capacity sits in China, giving Beijing genuine leverage — leverage it has already used, adding US firms to its own export control list in 2026 in direct response to American chip restrictions.

And in biotechnology, the dominance claim isn't just about manufacturing scale — it shows up in research quality. China's share of global patent publications rose from 45% in 2014 to 73% in 2024, and its biopharma patent filings have surged more than 300% over the past decade. More tellingly, the number of top-cited, high-impact Chinese biotechnology papers rose from roughly 139 in 2012 to 671 in 2022 — a 382% increase — while the equivalent US figure fell by about a third over the same period. That's not volume without substance. That's a genuine shift in where cutting-edge biotech research is actually happening.

The catch: volume isn't the same as value

Here's where I think the simple dominance narrative breaks down, and rare earths are the clearest example. China holds 81% of all rare-earth patent families filed between 2014 and 2024 — an overwhelming share by any raw count. But a study published in July 2026 in the Bulletin of the Chinese Academy of Sciences found that Japan and the United States control the patents behind more than 80% of the high-value applications built on those same materials: permanent magnets, catalysts, luminescent materials, and polishing compounds. Companies like Sumitomo, Shin-Etsu, and TDK hold the high-citation, commercially valuable intellectual property, even though China mines and processes the overwhelming majority of the raw material those patents depend on.

That's a genuinely important distinction, and it's the kind of nuance that gets lost when a statistic like "81% of patents" gets repeated without the second half of the sentence. China controls the supply chain. It does not yet control the highest-value technology built on top of that supply chain, at least not in rare earths specifically. Filing volume and value capture are two different games, and China is unambiguously winning one of them while still catching up on the other.

My honest assessment

I don't think this catch undermines the broader dominance case — it sharpens it. In EVs, batteries, and solar, China's advantage is structural and manufacturing-based, and manufacturing scale at this level is extraordinarily difficult to dislodge once it's built, regardless of who holds the fanciest patents. In biotechnology, the evidence increasingly suggests China isn't just manufacturing at scale but genuinely leading on research quality, measured by the metric researchers actually trust: citation impact, not just publication count. Rare earths are the one sector in this list where the reality is more mixed than the headline statistic suggests — dominant at the base of the supply chain, still behind at the top of the value chain.

The bigger point, and the one I'd want a reader to leave with, is this: China's technology position isn't a single story that's either "dominant" or "overhyped." It's a sector-by-sector picture, and the sectors where China has moved from manufacturing scale to genuine research and value-capture leadership — biotech chief among them — are the ones worth watching most closely, because that's the transition every industrial power eventually has to make if manufacturing dominance is going to translate into lasting economic power rather than just market share.